Desferal
(Deferoxamine)ApprovedSmall molecule
Alnylam PharmaceuticalsDeferoxamine is used to treat iron overload in the body, which can occur from repeated blood transfusions or certain blood disorders. It works by binding to excess iron so the body can eliminate it.[2] Desferal is currently approved and in use across 17 indications[4].[1]
Desferal is one of 407 small molecule programs targeting Blood Transfusion. It is currently in Approved.
17
Indications
28
Total Trials
6
Active Trials
406
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Desferal
Alnylam PharmaceuticalsApproved
Cymbalta
Alnylam PharmaceuticalsPreclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Spravato
WWim Janssens
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Avastin
RochePreclinical
Nubain
AAultman Health Foundation
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sickle Cell Disease3 trials
Thalassemia3 trials
Intracerebral Hemorrhage2 trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Terminated·—·Phase 2·NCT01662895·42 enrolled
Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage
Unknown status·—·Phase 1/2·NCT02367248·180 enrolled
COVID-192 trials
Subarachnoid Hemorrhage2 trials
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
Recruiting·—·Phase 2·NCT04566991·120 enrolled
16 more indications
Iron Overload1 trial
Pilot Study1 trial
Pilot Study for Patients With Poor Response to Deferasirox
Completed·—·Phase 4·NCT00749515·15 enrolled
Hemochromatosis1 trial
Acute Kidney Injury1 trial
Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury
Active, not recruiting·—·Phase 2·NCT04633889·320 enrolled
Allogeneic Stem Cell Transplantation1 trial
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
Terminated·—·N/A·NCT00658411·5 enrolled
Leptomeningeal Metastasis1 trial
Safety and Efficacy1 trial
Wound Healing1 trial
Ischemic stroke1 trial
Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke
Completed·—··NCT05748587·48 enrolled
Oxidative Stress1 trial
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
Completed·—·Phase 2/3·NCT04292314·350 enrolled
Blood Transfusion1 trial
Combination Therapy1 trial
Regulatory
FDA Approval Timeline[5]
May 25, 2000
DESFERAL
NDA NDA016267
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Desferal drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Deferoxamine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company